{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:11:56Z","timestamp":1780618316956,"version":"3.54.1"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","award":["T32 CA 009599"],"award-info":[{"award-number":["T32 CA 009599"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1245\/s10434-025-17069-3","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:35:21Z","timestamp":1740756921000},"page":"3672-3687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Educational Review: Updates on Therapeutic Strategies for Gastric Cancer with Peritoneal Metastasis"],"prefix":"10.1245","volume":"32","author":[{"given":"Kever A.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence P.","family":"Diggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Badgwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"3","key":"17069_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"17069_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5230\/jgc.2011.11.3.135","volume":"11","author":"A Shin","year":"2011","unstructured":"Shin A, Kim J, Park S. Gastric cancer epidemiology in Korea. J Gastric Cancer. 2011;11(3):135. https:\/\/doi.org\/10.5230\/jgc.2011.11.3.135.","journal-title":"J Gastric Cancer."},{"key":"17069_CR3","unstructured":"SEER Cancer Stat Facts: Stomach Cancer. Accessed 9\/16\/2024, https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html"},{"issue":"3","key":"17069_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.crad.2012.07.015","volume":"68","author":"S Burbidge","year":"2013","unstructured":"Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013;68(3):251\u20135. https:\/\/doi.org\/10.1016\/j.crad.2012.07.015.","journal-title":"Clin Radiol."},{"issue":"3","key":"17069_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, Van Gestel YR, Van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622\u20138. https:\/\/doi.org\/10.1002\/ijc.28373.","journal-title":"Int J Cancer."},{"issue":"2","key":"17069_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/jcm11020458","volume":"11","author":"Y Yonemura","year":"2022","unstructured":"Yonemura Y, Ishibashi H, Mizumoto A, et al. The development of peritoneal metastasis from gastric cancer and rationale of treatment according to the mechanism. J Clin Med. 2022;11(2):458. https:\/\/doi.org\/10.3390\/jcm11020458.","journal-title":"J Clin Med."},{"issue":"7","key":"17069_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/jso.23907","volume":"111","author":"B Badgwell","year":"2015","unstructured":"Badgwell B, Roy-Chowdhuri S, Chiang YJ, et al. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015;111(7):875\u201381. https:\/\/doi.org\/10.1002\/jso.23907.","journal-title":"J Surg Oncol."},{"issue":"4","key":"17069_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jamcollsurg.2014.03.062","volume":"219","author":"G Spolverato","year":"2014","unstructured":"Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219(4):664\u201375. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2014.03.062.","journal-title":"J Am Coll Surg."},{"key":"17069_CR9","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita V. Pharmacokinetic rationale for peritoneal drug administration. Cancer Treat Rep. 1978;62:1\u201313.","journal-title":"Cancer Treat Rep."},{"issue":"8","key":"17069_CR10","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1200\/jco.2002.08.105","volume":"20","author":"P Ross","year":"2002","unstructured":"Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996\u20132004. https:\/\/doi.org\/10.1200\/jco.2002.08.105.","journal-title":"J Clin Oncol."},{"key":"17069_CR11","doi-asserted-by":"publisher","first-page":"405652","DOI":"10.1155\/2012\/405652","volume":"2012","author":"KK Turaga","year":"2012","unstructured":"Turaga KK, Gamblin TC, Pappas S. Surgical treatment of peritoneal carcinomatosis from gastric cancer. Int J Surg Oncol. 2012;2012:405652. https:\/\/doi.org\/10.1155\/2012\/405652.","journal-title":"Int J Surg Oncol."},{"issue":"10","key":"17069_CR12","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1245\/s10434-008-0055-3","volume":"15","author":"B Badgwell","year":"2008","unstructured":"Badgwell B, Cormier JN, Krishnan S, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008;15(10):2684\u201391. https:\/\/doi.org\/10.1245\/s10434-008-0055-3.","journal-title":"Ann Surg Oncol."},{"issue":"24","key":"17069_CR13","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/jco.21.02745","volume":"40","author":"YX Gwee","year":"2022","unstructured":"Gwee YX, Chia DKA, So J, et al. Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis. J Clin Oncol. 2022;40(24):2830. https:\/\/doi.org\/10.1200\/jco.21.02745.","journal-title":"J Clin Oncol."},{"issue":"6","key":"17069_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(17)30336-4","volume":"18","author":"J Tseng","year":"2017","unstructured":"Tseng J, Bryan DS, Poli E, Sharma M, Polite BN, Turaga KK. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncol. 2017;18(6):711\u20132. https:\/\/doi.org\/10.1016\/S1470-2045(17)30336-4.","journal-title":"Lancet Oncol."},{"issue":"1","key":"17069_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4251\/wjgo.v2.i1.12","volume":"2","author":"S Kusamura","year":"2010","unstructured":"Kusamura S, Baratti D, Zaffaroni N, et al. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol. 2010;2(1):12\u20138. https:\/\/doi.org\/10.4251\/wjgo.v2.i1.12.","journal-title":"World J Gastrointest Oncol."},{"issue":"1","key":"17069_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/gutjnl-2019-319748","volume":"70","author":"JA Ajani","year":"2021","unstructured":"Ajani JA, Xu Y, Huo L, et al. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2021;70(1):55\u201366. https:\/\/doi.org\/10.1136\/gutjnl-2019-319748.","journal-title":"Gut."},{"issue":"1","key":"17069_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1242\/jcs.108.1.127","volume":"108","author":"S Yonemura","year":"1995","unstructured":"Yonemura S, Itoh M, Nagafuchi A, Tsukita S. Cell-to-cell adherens junction formation and actin filament organization: similarities and differences between non-polarized fibroblasts and polarized epithelial cells. J Cell Sci. 1995;108(1):127\u201342. https:\/\/doi.org\/10.1242\/jcs.108.1.127.","journal-title":"J Cell Sci."},{"issue":"5","key":"17069_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449\u201356. https:\/\/doi.org\/10.1038\/nm.3850.","journal-title":"Nat Med."},{"issue":"1","key":"17069_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/gutjnl-2018-318070","volume":"69","author":"R Wang","year":"2020","unstructured":"Wang R, Song S, Harada K, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69(1):18\u201331. https:\/\/doi.org\/10.1136\/gutjnl-2018-318070.","journal-title":"Gut."},{"key":"17069_CR20","doi-asserted-by":"publisher","first-page":"101846","DOI":"10.1016\/j.canep.2020.101846","volume":"69","author":"WJ Koemans","year":"2020","unstructured":"Koemans WJ, Luijten J, van der Kaaij RT, et al. The metastatic pattern of intestinal and diffuse type gastric carcinoma - A Dutch national cohort study. Cancer Epidemiol. 2020;69:101846. https:\/\/doi.org\/10.1016\/j.canep.2020.101846.","journal-title":"Cancer Epidemiol."},{"issue":"32","key":"17069_CR21","doi-asserted-by":"publisher","first-page":"52307","DOI":"10.18632\/oncotarget.10740","volume":"7","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307\u201316. https:\/\/doi.org\/10.18632\/oncotarget.10740.","journal-title":"Oncotarget."},{"issue":"6","key":"17069_CR22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/jso.25379","volume":"119","author":"D Solomon","year":"2019","unstructured":"Solomon D, Denicola N, Feingold D, et al. Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival. J Surg Oncol. 2019;119(6):758\u201365. https:\/\/doi.org\/10.1002\/jso.25379.","journal-title":"J Surg Oncol."},{"issue":"1","key":"17069_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10350-006-0741-9","volume":"50","author":"EM Murphy","year":"2007","unstructured":"Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum. 2007;50(1):37\u201342. https:\/\/doi.org\/10.1007\/s10350-006-0741-9.","journal-title":"Dis Colon Rectum."},{"issue":"4","key":"17069_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2298\/vsp0604349k","volume":"63","author":"Z Kosti\u0107","year":"2006","unstructured":"Kosti\u0107 Z, Cuk V, Bokun R, Ignjatovi\u0107 D, Usaj-Knezevi\u0107 S, Ignjatovi\u0107 M. Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma. Vojnosanit Pregl. 2006;63(4):349\u201356. https:\/\/doi.org\/10.2298\/vsp0604349k.","journal-title":"Vojnosanit Pregl."},{"issue":"2","key":"17069_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3892\/ijo.11.2.349","volume":"11","author":"Y Yonemura","year":"1997","unstructured":"Yonemura Y, Endou Y, Nojima M, et al. A possible role of cytokines in the formation of peritoneal dissemination. Int J Oncol. 1997;11(2):349\u201358. https:\/\/doi.org\/10.3892\/ijo.11.2.349.","journal-title":"Int J Oncol."},{"issue":"2","key":"17069_CR26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.47102\/annals-acadmedsg.V32N2p219","volume":"32","author":"DG Jayne","year":"2003","unstructured":"Jayne DG. The molecular biology of peritoneal carcinomatosis from gastrointestinal cancer. Ann Acad Med Singap. 2003;32(2):219\u201325.","journal-title":"Ann Acad Med Singap."},{"key":"17069_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-540-30760-0_2","volume":"169","author":"Y Yonemura","year":"2007","unstructured":"Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. Recent Results Cancer Res. 2007;169:11\u201323. https:\/\/doi.org\/10.1007\/978-3-540-30760-0_2.","journal-title":"Recent Results Cancer Res."},{"issue":"6","key":"17069_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/039139880703000610","volume":"30","author":"G Sacchi","year":"2007","unstructured":"Sacchi G, Di Paolo N, Venezia F, Rossi A, Nicolai GA, Garosi G. Possible role of milky spots in mesothelial transplantation. Int J Artif Organs. 2007;30(6):520\u20136. https:\/\/doi.org\/10.1177\/039139880703000610.","journal-title":"Int J Artif Organs."},{"issue":"3","key":"17069_CR29","doi-asserted-by":"publisher","first-page":"e15914","DOI":"10.15252\/emmm.202215914","volume":"15","author":"S Bootsma","year":"2023","unstructured":"Bootsma S, Bijlsma MF, Vermeulen L. The molecular biology of peritoneal metastatic disease. EMBO Mol Med. 2023;15(3):e15914. https:\/\/doi.org\/10.15252\/emmm.202215914.","journal-title":"EMBO Mol Med."},{"issue":"4","key":"17069_CR30","first-page":"809","volume":"18","author":"T Kawamura","year":"2001","unstructured":"Kawamura T, Endo Y, Yonemura Y, et al. Significance of integrin alpha2\/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. Int J Oncol. 2001;18(4):809\u201315.","journal-title":"Int J Oncol."},{"issue":"21","key":"17069_CR31","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1158\/0008-5472.Can-23-3074","volume":"84","author":"X Liu","year":"2024","unstructured":"Liu X, Chen B, Xie F, et al. FOXP4 Is a Direct YAP1 target that promotes gastric cancer stemness and drives metastasis. Cancer Res. 2024;84(21):3574\u201388. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-3074.","journal-title":"Cancer Res."},{"issue":"2","key":"17069_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bbcan.2012.05.002","volume":"1826","author":"J Paredes","year":"2012","unstructured":"Paredes J, Figueiredo J, Albergaria A, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826(2):297\u2013311. https:\/\/doi.org\/10.1016\/j.bbcan.2012.05.002.","journal-title":"Biochim Biophys Acta."},{"issue":"6","key":"17069_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11523-024-01097-2","volume":"19","author":"LW Wu","year":"2024","unstructured":"Wu LW, Jang SJ, Shapiro C, et al. Diffuse gastric cancer: a comprehensive review of molecular features and emerging therapeutics. Target Oncol. 2024;19(6):845\u201365. https:\/\/doi.org\/10.1007\/s11523-024-01097-2.","journal-title":"Target Oncol."},{"issue":"6","key":"17069_CR34","first-page":"2757","volume":"17","author":"H Rashid","year":"2016","unstructured":"Rashid H, Alam K, Afroze D, Yousuf A, Banday M, Kawoosa F. Hypermethylation status of E-Cadherin gene in gastric cancer patients in a high incidence area. Asian Pac J Cancer Prev. 2016;17(6):2757\u201360.","journal-title":"Asian Pac J Cancer Prev."},{"issue":"1","key":"17069_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2014.168.","journal-title":"JAMA Oncol."},{"issue":"2","key":"17069_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.cd-19-0811","volume":"10","author":"H Zhang","year":"2020","unstructured":"Zhang H, Schaefer A, Wang Y, et al. Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov. 2020;10(2):288\u2013305. https:\/\/doi.org\/10.1158\/2159-8290.cd-19-0811.","journal-title":"Cancer Discov."},{"issue":"5","key":"17069_CR37","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33(5):1100\u20137. https:\/\/doi.org\/10.1007\/s10637-015-0282-y.","journal-title":"Invest New Drugs."},{"issue":"3","key":"17069_CR38","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms23031726","volume":"23","author":"H-H Chuang","year":"2022","unstructured":"Chuang H-H, Zhen Y-Y, Tsai Y-C, et al. FAK in cancer: from mechanisms to therapeutic strategies. Int J Mol Sci. 2022;23(3):1726. https:\/\/doi.org\/10.3390\/ijms23031726.","journal-title":"Int J Mol Sci."},{"issue":"13","key":"17069_CR39","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1158\/0008-5472.Can-12-3937","volume":"73","author":"N Ishii","year":"2013","unstructured":"Ishii N, Harada N, Joseph EW, et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 2013;73(13):4050\u201360. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-3937.","journal-title":"Cancer Res."},{"issue":"Suppl. 16","key":"17069_CR40","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","volume":"41","author":"SN Banerjee","year":"2023","unstructured":"Banerjee SN, Ring KL, Van Nieuwenhuysen E, et al. Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: a phase 2 study of avutometinib (VS-6766)\u00b1defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol. 2023;41(Suppl. 16):5515.","journal-title":"J Clin Oncol."},{"key":"17069_CR41","doi-asserted-by":"crossref","unstructured":"Lim K-H, Spencer KR, Safyan RA, et al. Avutometinib\/defactinib and gemcitabine\/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b\/2 study (RAMP 205). Am Soc Clin Oncol; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.4140"},{"issue":"13","key":"17069_CR42","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1245\/s10434-016-5409-7","volume":"23","author":"N Ikoma","year":"2016","unstructured":"Ikoma N, Blum M, Chiang Y-J, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23(13):4332\u20137. https:\/\/doi.org\/10.1245\/s10434-016-5409-7.","journal-title":"Ann Surg Oncol."},{"key":"17069_CR43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-030-62640-2_6","volume-title":"Periton Tumor Metast Surg Intraperiton Syst Ther","author":"J Tepel","year":"2021","unstructured":"Tepel J, Ajah D. The Natural Course of Peritoneal carcinomatosis (PC). In: B Rau, A K\u00f6nigsrainer, F Mohamed, PH Sugarbaker, editors. Periton Tumor Metast Surg Intraperiton Syst Ther. Springer International Publishing; 2021. p. 55\u20138."},{"issue":"9","key":"17069_CR44","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","volume":"24","author":"N Ikoma","year":"2017","unstructured":"Ikoma N, Chen H-C, Wang X, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24(9):2679\u201387. https:\/\/doi.org\/10.1245\/s10434-017-5838-y.","journal-title":"Ann Surg Oncol."},{"key":"17069_CR45","unstructured":"National Comprehensive Cancer Network. Gastric Cancer (Version 4.2024). Accessed 8\/30\/2024, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf"},{"issue":"1","key":"17069_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/jso.25094","volume":"118","author":"CA Thiels","year":"2018","unstructured":"Thiels CA, Ikoma N, Fournier K, et al. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. 2018;118(1):61\u20137. https:\/\/doi.org\/10.1002\/jso.25094.","journal-title":"J Surg Oncol."},{"issue":"4","key":"17069_CR47","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/jso.24912","volume":"117","author":"D Mizrak Kaya","year":"2018","unstructured":"Mizrak Kaya D, Nogueras-Gonz\u00e1lez GM, Harada K, et al. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2018;117(4):678\u201384. https:\/\/doi.org\/10.1002\/jso.24912.","journal-title":"J Surg Oncol."},{"issue":"8","key":"17069_CR48","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/jso.25729","volume":"120","author":"CJ Allen","year":"2019","unstructured":"Allen CJ, Newhook TE, Vreeland TJ, et al. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol. 2019;120(8):1350\u20137. https:\/\/doi.org\/10.1002\/jso.25729.","journal-title":"J Surg Oncol."},{"key":"17069_CR49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cca.2014.10.014","volume":"439","author":"K Nakabayashi","year":"2015","unstructured":"Nakabayashi K, Uraoka T, Shibuya M, Matsuura N, Tsujimoto M. Rapid detection of CEA mRNA in peritoneal washes using one-step nucleic acid amplification (OSNA\u00ae) for gastric cancer patients. Clinica Chimica Acta. 2015;439:137\u201342.","journal-title":"Clinica Chimica Acta."},{"issue":"3","key":"17069_CR50","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.21873\/anticanres.12347","volume":"38","author":"E Virgilio","year":"2018","unstructured":"Virgilio E, Giarnieri E, Giovagnoli MR, et al. Gastric cancer cells in peritoneal lavage fluid: a systematic review comparing cytological with molecular detection for diagnosis of peritoneal metastases and prediction of peritoneal recurrences. Anticancer Res. 2018;38(3):1255\u201362. https:\/\/doi.org\/10.21873\/anticanres.12347.","journal-title":"Anticancer Res."},{"issue":"24","key":"17069_CR51","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/s41388-024-03034-z","volume":"43","author":"K van der Sluis","year":"2024","unstructured":"van der Sluis K, van Sandick JW, Vollebergh MA, et al. Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid. Oncogene. 2024;43(24):1877\u201382. https:\/\/doi.org\/10.1038\/s41388-024-03034-z.","journal-title":"Oncogene."},{"issue":"1","key":"17069_CR52","doi-asserted-by":"publisher","first-page":"e2032269","DOI":"10.1001\/jamanetworkopen.2020.32269","volume":"4","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Liang X, Wang W, et al. Noninvasive prediction of occult peritoneal metastasis in gastric cancer using deep learning. JAMA Netw Open. 2021;4(1):e2032269. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.32269.","journal-title":"JAMA Netw Open."},{"issue":"6","key":"17069_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000436972","volume":"89","author":"N Charalampakis","year":"2015","unstructured":"Charalampakis N, Xiao L, Elimova E, et al. Initial standardized uptake value of positron emission tomography influences the prognosis of patients with localized gastric adenocarcinoma treated preoperatively. Oncology. 2015;89(6):305\u201310. https:\/\/doi.org\/10.1159\/000436972.","journal-title":"Oncology."},{"issue":"10","key":"17069_CR54","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1159\/000517842","volume":"99","author":"A Abdelhakeem","year":"2021","unstructured":"Abdelhakeem A, Patnana M, Wang X, et al. Influence of baseline positron emission tomography in metastatic gastroesophageal cancer on survival and response to therapy. Oncology. 2021;99(10):659\u201364. https:\/\/doi.org\/10.1159\/000517842.","journal-title":"Oncology."},{"issue":"4","key":"17069_CR55","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2214\/ajr.22.28402","volume":"220","author":"Z Gege","year":"2023","unstructured":"Gege Z, Xueju W, Bin J. Head-to-head comparison of (68)Ga-FAPI PET\/CT and FDG PET\/CT for the detection of peritoneal metastases: systematic review and meta-analysis. AJR Am J Roentgenol. 2023;220(4):490\u20138. https:\/\/doi.org\/10.2214\/ajr.22.28402.","journal-title":"AJR Am J Roentgenol."},{"issue":"1","key":"17069_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.123.266329","volume":"65","author":"W Xu","year":"2024","unstructured":"Xu W, Cai J, Peng T, et al. Fibroblast activation protein-targeted PET\/CT with (18)F-fibroblast activation protein inhibitor-74 for evaluation of gastrointestinal cancer: comparison with (18)F-FDG PET\/CT. J Nucl Med. 2024;65(1):40\u201351. https:\/\/doi.org\/10.2967\/jnumed.123.266329.","journal-title":"J Nucl Med."},{"key":"17069_CR57","unstructured":"Gonzalez EM. 18F-Fibroblast activation protein inhibitor ([18F]FAPI-74) PET imaging for cancer detection. National Library of Medicine (US). Accessed 12\/9\/2024. https:\/\/clinicaltrials.gov\/study\/NCT06503146"},{"key":"17069_CR58","unstructured":"Bentestuen MM. [68Ga]Ga-FAPI PET\/CT: the dagnostic accuracy for primary staging and re-staging after chemotherapy in patients with gastric and gastro-esophageal junctional cancer. National Library of Medicine (US). Accessed 12\/9\/2024. https:\/\/clinicaltrials.gov\/study\/NCT05898854"},{"issue":"5","key":"17069_CR59","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1245\/s10434-014-4041-7","volume":"22","author":"RN Low","year":"2015","unstructured":"Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708\u201315. https:\/\/doi.org\/10.1245\/s10434-014-4041-7.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"17069_CR60","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.4240\/wjgs.v15.i10.2280","volume":"15","author":"SYA Ho","year":"2023","unstructured":"Ho SYA, Tay KV. Systematic review of diagnostic tools for peritoneal metastasis in gastric cancer-staging laparoscopy and its alternatives. World J Gastrointest Surg. 2023;15(10):2280\u201393. https:\/\/doi.org\/10.4240\/wjgs.v15.i10.2280.","journal-title":"World J Gastrointest Surg."},{"key":"17069_CR61","doi-asserted-by":"publisher","first-page":"106727","DOI":"10.1016\/j.crad.2024.10.008","volume":"80","author":"ZN Zhu","year":"2024","unstructured":"Zhu ZN, Feng QX, Li Q, Xu WY, Liu XS. Machine learning-based CT radiomics approach for predicting occult peritoneal metastasis in advanced gastric cancer preoperatively. Clin Radiol. 2024;80:106727. https:\/\/doi.org\/10.1016\/j.crad.2024.10.008.","journal-title":"Clin Radiol."},{"issue":"2","key":"17069_CR62","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bjc.2015.417","volume":"114","author":"Y Li","year":"2016","unstructured":"Li Y, Gong J, Zhang Q, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 2016;114(2):138\u201345. https:\/\/doi.org\/10.1038\/bjc.2015.417.","journal-title":"Br J Cancer."},{"issue":"3","key":"17069_CR63","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/cancers12030592","volume":"12","author":"A Sanjeevaiah","year":"2020","unstructured":"Sanjeevaiah A, Park H, Fangman B, Porembka M. Gastric cancer with radiographically occult metastatic disease: biology, challenges, and diagnostic approaches. Cancers. 2020;12(3):592. https:\/\/doi.org\/10.3390\/cancers12030592.","journal-title":"Cancers."},{"key":"17069_CR64","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/1471-2407-13-314","volume":"13","author":"L Tang","year":"2013","unstructured":"Tang L, Zhao S, Liu W, et al. Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer. 2013;13:314. https:\/\/doi.org\/10.1186\/1471-2407-13-314.","journal-title":"BMC Cancer."},{"issue":"3","key":"17069_CR65","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tranon.2017.02.007","volume":"10","author":"X Zheng","year":"2017","unstructured":"Zheng X, Fan L, Zhou P, et al. Detection of circulating tumor cells and circulating tumor microemboli in gastric cancer. Transl Oncol. 2017;10(3):431\u201341. https:\/\/doi.org\/10.1016\/j.tranon.2017.02.007.","journal-title":"Transl Oncol."},{"issue":"15","key":"17069_CR66","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.3390\/cancers16152692","volume":"16","author":"M Ratti","year":"2024","unstructured":"Ratti M, Orlandi E, Toscani I, et al. Emerging therapeutic targets and future directions in advanced gastric cancer: a comprehensive review. Cancers. 2024;16(15):2692.","journal-title":"Cancers."},{"issue":"11","key":"17069_CR67","doi-asserted-by":"publisher","first-page":"9421","DOI":"10.3390\/ijms24119421","volume":"24","author":"G Grizzi","year":"2023","unstructured":"Grizzi G, Salati M, Bonomi M, et al. Circulating tumor DNA in gastric adenocarcinoma: future clinical applications and perspectives. Int J Mol Sci. 2023;24(11):9421. https:\/\/doi.org\/10.3390\/ijms24119421.","journal-title":"Int J Mol Sci."},{"issue":"10","key":"17069_CR68","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41419-019-1907-4","volume":"10","author":"Z Chen","year":"2019","unstructured":"Chen Z, Zhang C, Zhang M, et al. Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer. Cell Death Dis. 2019;10(10):697. https:\/\/doi.org\/10.1038\/s41419-019-1907-4.","journal-title":"Cell Death Dis."},{"issue":"1","key":"17069_CR69","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1245\/s10434-022-12399-y","volume":"30","author":"BG Sullivan","year":"2023","unstructured":"Sullivan BG, Lo A, Yu J, et al. Circulating tumor DNA is unreliable to detect somatic gene alterations in gastrointestinal peritoneal carcinomatosis. Ann Surg Oncol. 2023;30(1):278\u201384. https:\/\/doi.org\/10.1245\/s10434-022-12399-y.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17069_CR70","doi-asserted-by":"publisher","first-page":"99225","DOI":"10.1186\/s12885-022-09922-5","volume":"22","author":"H Wu","year":"2022","unstructured":"Wu H, Ji H, Yang W, et al. Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers. BMC Cancer. 2022;22(1):99225. https:\/\/doi.org\/10.1186\/s12885-022-09922-5.","journal-title":"BMC Cancer."},{"issue":"1","key":"17069_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10238-024-01310-6","volume":"24","author":"MR Eskandarion","year":"2024","unstructured":"Eskandarion MR, Eskandarieh S, Tutunchi S, Shakoori Farahani A, Shirkoohi R. Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis. Clin Exp Med. 2024;24(1):59. https:\/\/doi.org\/10.1007\/s10238-024-01310-6.","journal-title":"Clin Exp Med."},{"issue":"7","key":"17069_CR72","first-page":"1415","volume":"24","author":"T Fujimura","year":"1989","unstructured":"Fujimura T, Yonemura Y, Urade M, et al. Continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C for peritoneal dissemination in gastric cancer. Nihon Gan Chiryo Gakkai Shi. 1989;24(7):1415\u201324.","journal-title":"Nihon Gan Chiryo Gakkai Shi."},{"issue":"6","key":"17069_CR73","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1245\/s10434-020-08320-0","volume":"27","author":"The Chicago Consensus on peritoneal surface malignancies","year":"2020","unstructured":"The Chicago Consensus on peritoneal surface malignancies. management of gastric metastases. Ann Surg Oncol. 2020;27(6):1768\u201373. https:\/\/doi.org\/10.1245\/s10434-020-08320-0.","journal-title":"Ann Surg Oncol."},{"key":"17069_CR74","unstructured":"Turaga KK. Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases. Cold Spring Harbor Laboratory; 2024."},{"issue":"1","key":"17069_CR75","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12\u201326. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.019.","journal-title":"Eur J Surg Oncol."},{"key":"17069_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/521487","volume":"2012","author":"Y Yonemura","year":"2012","unstructured":"Yonemura Y, Elnemr A, Endou Y, et al. Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named Aqua Dissection. Gastroenterol Res Pract. 2012;2012:1\u201310. https:\/\/doi.org\/10.1155\/2012\/521487.","journal-title":"Gastroenterol Res Pract."},{"issue":"2","key":"17069_CR77","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5230\/jgc.2014.14.2.117","volume":"14","author":"I K\u00f6nigsrainer","year":"2014","unstructured":"K\u00f6nigsrainer I, Horvath P, Struller F, K\u00f6nigsrainer A, Beckert S. Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer. 2014;14(2):117. https:\/\/doi.org\/10.5230\/jgc.2014.14.2.117.","journal-title":"J Gastric Cancer."},{"issue":"3","key":"17069_CR78","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(15)00553-7.","journal-title":"Lancet Oncol."},{"issue":"3","key":"17069_CR79","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321. https:\/\/doi.org\/10.1016\/s1470-2045(08)70035-4.","journal-title":"Lancet Oncol."},{"issue":"1","key":"17069_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/nejmoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36\u201346. https:\/\/doi.org\/10.1056\/nejmoa073149.","journal-title":"N Engl J Med."},{"issue":"10294","key":"17069_CR81","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2.","journal-title":"Lancet."},{"issue":"11","key":"17069_CR82","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol."},{"issue":"10111","key":"17069_CR83","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/s0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(17)31827-5.","journal-title":"Lancet."},{"issue":"9742","key":"17069_CR84","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0140-6736(10)61121-x","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(10)61121-x.","journal-title":"Lancet."},{"issue":"5","key":"17069_CR85","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2020-0737","volume":"17","author":"HC Chung","year":"2021","unstructured":"Chung HC, Bang Y-J, Fuchs S, et al. First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in Her2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 2021;17(5):491\u2013501. https:\/\/doi.org\/10.2217\/fon-2020-0737.","journal-title":"Future Oncol."},{"issue":"11","key":"17069_CR86","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/s1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(14)70420-6.","journal-title":"Lancet Oncol."},{"issue":"9911","key":"17069_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(13)61719-5.","journal-title":"Lancet."},{"issue":"20","key":"17069_CR88","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/jco.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343. https:\/\/doi.org\/10.1200\/jco.2003.04.187.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17069_CR89","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69\u201376. https:\/\/doi.org\/10.1016\/s1470-2045(05)70539-8.","journal-title":"Lancet Oncol."},{"issue":"1","key":"17069_CR90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29\u201342. https:\/\/doi.org\/10.1097\/00000658-199501000-00004.","journal-title":"Ann Surg."},{"issue":"6","key":"17069_CR91","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ejso.2020.11.140","volume":"47","author":"A Arjona-Sanchez","year":"2021","unstructured":"Arjona-Sanchez A, Aziz O, Passot G, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Eur J Surg Oncol. 2021;47(6):1420\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2020.11.140.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"17069_CR92","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s00464-018-6352-4","volume":"33","author":"A Arjona-Sanchez","year":"2019","unstructured":"Arjona-Sanchez A, Esquivel J, Glehen O, et al. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: the American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. Surg Endosc. 2019;33(3):854\u201360. https:\/\/doi.org\/10.1007\/s00464-018-6352-4.","journal-title":"Surg Endosc."},{"issue":"2","key":"17069_CR93","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/jco.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42(2):146\u201356. https:\/\/doi.org\/10.1200\/jco.22.02867.","journal-title":"J Clin Oncol."},{"issue":"6","key":"17069_CR94","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"X-J Yang","year":"2011","unstructured":"Yang X-J, Huang C-Q, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381. https:\/\/doi.org\/10.1245\/s10434-011-1631-5.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"17069_CR95","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370\u20137. https:\/\/doi.org\/10.1245\/s10434-010-1039-7.","journal-title":"Ann Surg Oncol."},{"issue":"473","key":"17069_CR96","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1098\/rstl.1744.0006","volume":"43","author":"C Warrick","year":"1997","unstructured":"Warrick C. An improvement on the practice of tapping; whereby that operation, instead of a relief for symptoms, becomes an absolute cure for an ascites, exemplified in the case of Jane Roman; and recommended to the consideration of the Royal Society, by Christo. Philos Trans R Soc Lond. 1997;43(473):12\u20139. https:\/\/doi.org\/10.1098\/rstl.1744.0006.","journal-title":"Philos Trans R Soc Lond."},{"issue":"18","key":"17069_CR97","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1001\/jama.1955.02960350004002","volume":"159","author":"AS Weisberger","year":"1955","unstructured":"Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA. 1955;159(18):4002. https:\/\/doi.org\/10.1001\/jama.1955.02960350004002.","journal-title":"JAMA."},{"issue":"2","key":"17069_CR98","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","volume":"7","author":"WP Ceelen","year":"2010","unstructured":"Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7(2):108\u201315. https:\/\/doi.org\/10.1038\/nrclinonc.2009.217.","journal-title":"Nat Rev Clin Oncol."},{"issue":"13","key":"17069_CR99","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1245\/s10434-020-08842-7","volume":"27","author":"MG White","year":"2020","unstructured":"White MG, Kothari A, Ikoma N, et al. Factors associated with resection and survival after laparoscopic HIPEC for peritoneal gastric cancer metastasis. Ann Surg Oncol. 2020;27(13):4963\u20139. https:\/\/doi.org\/10.1245\/s10434-020-08842-7.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17069_CR100","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","volume":"19","author":"WJ Koemans","year":"2019","unstructured":"Koemans WJ, van der Kaaij RT, Boot H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19(1):420. https:\/\/doi.org\/10.1186\/s12885-019-5640-2.","journal-title":"BMC Cancer."},{"key":"17069_CR101","unstructured":"van Sandick JW. Personal communication regarding status of PERISCOPE-II trial. 2024."},{"issue":"5","key":"17069_CR102","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1200\/jco.1994.12.5.970","volume":"12","author":"T Sautner","year":"1994","unstructured":"Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol. 1994;12(5):970\u20134. https:\/\/doi.org\/10.1200\/jco.1994.12.5.970.","journal-title":"J Clin Oncol."},{"issue":"12","key":"17069_CR103","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/jco.1995.13.12.2961","volume":"13","author":"P Francis","year":"1995","unstructured":"Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study. J Clin Oncol. 1995;13(12):2961\u20137. https:\/\/doi.org\/10.1200\/jco.1995.13.12.2961.","journal-title":"J Clin Oncol."},{"issue":"3","key":"17069_CR104","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11605-016-3336-3","volume":"21","author":"DY Chan","year":"2017","unstructured":"Chan DY, Syn NL, Yap R, et al. Conversion surgery post-intraperitoneal paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. Are we ready? J Gastrointest Surg. 2017;21(3):425\u201333. https:\/\/doi.org\/10.1007\/s11605-016-3336-3.","journal-title":"J Gastrointest Surg."},{"issue":"19","key":"17069_CR105","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/jco.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018;36(19):1922\u20139. https:\/\/doi.org\/10.1200\/jco.2018.77.8613.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17069_CR106","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1186\/s13063-022-06143-w","volume":"23","author":"Y Bin","year":"2022","unstructured":"Bin Y, Lan D, Bao W, et al. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation. Trials. 2022;23(1):6143. https:\/\/doi.org\/10.1186\/s13063-022-06143-w.","journal-title":"Trials"},{"issue":"10","key":"17069_CR107","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2021-1414","volume":"18","author":"S Lu","year":"2022","unstructured":"Lu S, Yang Z-Y, Yan C, et al. A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis. Future Oncol. 2022;18(10):1175\u201383. https:\/\/doi.org\/10.2217\/fon-2021-1414.","journal-title":"Future Oncol."},{"key":"17069_CR108","first-page":"327","volume":"43","author":"ZY Chao Yan","year":"2025","unstructured":"Chao Yan ZY, Shi Z, Sheng L, Shi M, Nie M, Chen J, Dan W, Mou Y, Yunyun X, Wang Y, Liu X, Cao H, Jiayi G, Jiren Y, Liu K, Liu X, Zhang J, Yin K, Zhu Z. Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 DRAGON-01 trial. J Clin Oncol. 2025;43:327.","journal-title":"J Clin Oncol."},{"issue":"9","key":"17069_CR109","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3390\/cancers14092334","volume":"14","author":"S Kim","year":"2022","unstructured":"Kim S, Lee C-M, Lee D, Kim J-H, Park S, Park S-H. Can we reboot the role of intraperitoneal chemotherapy in the treatment for gastric cancer with peritoneal carcinomatosis?: a retrospective cohort study regarding minimally invasive surgery conjoined with intraperitoneal plus systemic chemotherapy. Cancers. 2022;14(9):2334. https:\/\/doi.org\/10.3390\/cancers14092334.","journal-title":"Cancers."},{"issue":"6","key":"17069_CR110","doi-asserted-by":"publisher","first-page":"794","DOI":"10.21147\/j.issn.1000-9604.2020.06.12","volume":"32","author":"Z Lei","year":"2020","unstructured":"Lei Z, Wang J, Li Z, et al. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a multicenter propensity score-matched cohort study. Chin J Cancer Res. 2020;32(6):794\u2013803. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2020.06.12.","journal-title":"Chin J Cancer Res."},{"issue":"2","key":"17069_CR111","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3892\/mco.2016.918","volume":"5","author":"M Yuan","year":"2016","unstructured":"Yuan M, Wang Z, Hu G, et al. A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Mol Clin Oncol. 2016;5(2):395\u20139. https:\/\/doi.org\/10.3892\/mco.2016.918.","journal-title":"Mol Clin Oncol."},{"issue":"2","key":"17069_CR112","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","volume":"24","author":"Y Yonemura","year":"2017","unstructured":"Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal\/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24(2):478\u201385. https:\/\/doi.org\/10.1245\/s10434-016-5487-6.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"17069_CR113","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","volume":"24","author":"B Badgwell","year":"2017","unstructured":"Badgwell B, Blum M, Das P, et al. Phase II Trial of Laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338\u201344. https:\/\/doi.org\/10.1245\/s10434-017-6047-4.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"17069_CR114","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1245\/s10434-020-08968-8","volume":"27","author":"AN Blumenthaler","year":"2020","unstructured":"Blumenthaler AN, Allen CJ, Ikoma N, et al. Laparoscopic HIPEC for low-volume peritoneal metastasis in gastric and gastroesophageal adenocarcinoma. Ann Surg Oncol. 2020;27(13):5047\u201356. https:\/\/doi.org\/10.1245\/s10434-020-08968-8.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17069_CR115","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","volume":"26","author":"W Solass","year":"2012","unstructured":"Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26(3):847\u201352. https:\/\/doi.org\/10.1007\/s00464-011-1964-y.","journal-title":"Surg Endosc."},{"issue":"21","key":"17069_CR116","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.3390\/jcm12216799","volume":"12","author":"SK Daniel","year":"2023","unstructured":"Daniel SK, Sun BJ, Lee B. PIPAC for gastrointestinal malignancies. J Clin Med. 2023;12(21):6799.","journal-title":"J Clin Med."},{"issue":"11","key":"17069_CR117","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","volume":"142","author":"V Khosrawipour","year":"2016","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJ, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142(11):2275\u201380. https:\/\/doi.org\/10.1007\/s00432-016-2234-0.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"17069_CR118","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","volume":"244","author":"P Esquis","year":"2006","unstructured":"Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244(1):106\u201312. https:\/\/doi.org\/10.1097\/01.sla.0000218089.61635.5f.","journal-title":"Ann Surg."},{"issue":"5","key":"17069_CR119","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/00001813-199607000-00016","volume":"7","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drug. 1996;7(5):596\u2013603. https:\/\/doi.org\/10.1097\/00001813-199607000-00016.","journal-title":"Anticancer Drug."},{"issue":"6","key":"17069_CR120","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/SLA.0b013e3182582b38","volume":"256","author":"O Facy","year":"2012","unstructured":"Facy O, Al Samman S, Magnin G, et al. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg. 2012;256(6):1084\u20138. https:\/\/doi.org\/10.1097\/SLA.0b013e3182582b38.","journal-title":"Ann Surg."},{"issue":"4","key":"17069_CR121","doi-asserted-by":"publisher","first-page":"20190013","DOI":"10.1515\/pp-2019-0013","volume":"5","author":"V Shree","year":"2020","unstructured":"Shree V, Lim TJ, Lean LL, So BYJ, Kim G. Anaesthesia considerations and techniques for pressurised intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2020;5(4):20190013. https:\/\/doi.org\/10.1515\/pp-2019-0013.","journal-title":"Pleura Peritoneum."},{"key":"17069_CR122","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"14","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14:128. https:\/\/doi.org\/10.1186\/s12957-016-0892-7.","journal-title":"World J Surg Oncol."},{"issue":"3","key":"17069_CR123","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10585-018-9895-9","volume":"35","author":"M Graversen","year":"2018","unstructured":"Graversen M, Detlefsen S, Pfeiffer P, Lundell L, Mortensen MB. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis. 2018;35(3):103\u20138. https:\/\/doi.org\/10.1007\/s10585-018-9895-9.","journal-title":"Clin Exp Metastasis."},{"issue":"5","key":"17069_CR124","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1245\/s10434-022-13010-0","volume":"30","author":"M Graversen","year":"2023","unstructured":"Graversen M, Detlefsen S, Ainsworth AP, et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study. Ann Surg Oncol. 2023;30(5):2634\u201344. https:\/\/doi.org\/10.1245\/s10434-022-13010-0.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"17069_CR125","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/pp-2016-0017","volume":"1","author":"V Khomyakov","year":"2019","unstructured":"Khomyakov V, Ryabov A, Ivanov A, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2019;1(3):159\u201366. https:\/\/doi.org\/10.1515\/pp-2016-0017.","journal-title":"Pleura Peritoneum."},{"key":"17069_CR126","doi-asserted-by":"publisher","first-page":"175883591984640","DOI":"10.1177\/1758835919846402","volume":"11","author":"F Struller","year":"2019","unstructured":"Struller F, Horvath P, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:175883591984640. https:\/\/doi.org\/10.1177\/1758835919846402.","journal-title":"Ther Adv Med Oncol."},{"issue":"3","key":"17069_CR127","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1515\/pp-2022-0111","volume":"7","author":"F Casella","year":"2022","unstructured":"Casella F, Bencivenga M, Rosati R, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne. Pleura Peritoneum. 2022;7(3):135\u201341. https:\/\/doi.org\/10.1515\/pp-2022-0111.","journal-title":"Pleura Peritoneum."},{"issue":"5","key":"17069_CR128","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1245\/s10434-024-14953-2","volume":"31","author":"B Badgwell","year":"2024","unstructured":"Badgwell B, Estrella J, Roy-Chowdhuri S, et al. Updated analysis of a phase 2 trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with peritoneal carcinoma from gastric cancer. Ann Surg Oncol. 2024;31(5):2824\u20135. https:\/\/doi.org\/10.1245\/s10434-024-14953-2.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"17069_CR129","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/jso.26366","volume":"123","author":"WJ Koemans","year":"2021","unstructured":"Koemans WJ, van der Kaaij RT, Wassenaar ECE, et al. Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial. J Surg Oncol. 2021;123(4):904\u201310. https:\/\/doi.org\/10.1002\/jso.26366.","journal-title":"J Surg Oncol."},{"issue":"1","key":"17069_CR130","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1186\/s12885-020-07601-x","volume":"20","author":"P Yu","year":"2020","unstructured":"Yu P, Ye Z, Dai G, et al. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study. BMC Cancer. 2020;20(1):1108. https:\/\/doi.org\/10.1186\/s12885-020-07601-x.","journal-title":"BMC Cancer."},{"issue":"1","key":"17069_CR131","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2021","unstructured":"Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28(1):258\u201364. https:\/\/doi.org\/10.1245\/s10434-020-08739-5.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"17069_CR132","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.gassur.2024.04.030","volume":"28","author":"M Cho","year":"2024","unstructured":"Cho M, Kim HS, Jung M, Hyung WJ. Perioperative intraperitoneal plus systemic chemotherapy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gastric cancer: phase Ib\/II single-arm prospective study. J Gastrointest Surg. 2024;28(7):1095\u2013103. https:\/\/doi.org\/10.1016\/j.gassur.2024.04.030.","journal-title":"J Gastrointest Surg."},{"issue":"2","key":"17069_CR133","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","volume":"31","author":"D Kobayashi","year":"2024","unstructured":"Kobayashi D, Kodera Y, Fukushima R, et al. Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2024;31(2):735\u201343. https:\/\/doi.org\/10.1245\/s10434-023-14240-6.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"17069_CR134","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/cam4.5277","volume":"12","author":"L Tu","year":"2023","unstructured":"Tu L, Zhang W, Ni L, et al. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: a phase II single-arm clinical trial. Cancer Med. 2023;12(4):4161\u20139. https:\/\/doi.org\/10.1002\/cam4.5277.","journal-title":"Cancer Med."},{"issue":"13","key":"17069_CR135","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","volume":"29","author":"DKA Chia","year":"2022","unstructured":"Chia DKA, Sundar R, Kim G, et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022;29(13):8597\u2013605. https:\/\/doi.org\/10.1245\/s10434-022-11998-z.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17069_CR136","first-page":"211","volume":"26","author":"Y Li","year":"2021","unstructured":"Li Y, Lin H, Huang K, Zhao J. Efficacy of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy in treating peritoneal metastasis of gastric cancer. J Buon. 2021;26(1):211\u20137.","journal-title":"J Buon."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17069-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T07:16:18Z","timestamp":1744096578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17069-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":136,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["17069"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17069-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no relevant disclosures. This work was supported by the National Institutes of Health T32 CA 009599 and the MD Anderson Cancer Center support grant (P30 CA016672).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}